Table 1.
Basic information.
| Basic Information | Number |
|---|---|
| Patients | 136 |
| Sex | |
| male | 94 (69.1%) |
| female | 42 (30.9%) |
| Age | 64 (60–70) |
| <60 | 33 (24.3%) |
| ≥60 | 103 (75.7%) |
| Histology | |
| Non-squamous carcinoma | 75 (55.1%) |
| Squamous carcinoma | 61 (44.9%) |
| Line of therapy | |
| First line | 71 (52.2%) |
| Second line | 47 (34.6%) |
| Third line and beyond | 10 (13.2%) |
| Combined chemotherapy | |
| No | 32 (23.5%) |
| Yes | 104 (76.5%) |
| Smoking status | |
| No | 52 (38.2%) |
| Yes | 84 (61.8%) |
| Drinking status | |
| no | 96 (70.6%) |
| yes | 40 (29.4%) |
| ECOG PS | |
| 0 | 70 (51.5%) |
| 1 | 53 (39.0%) |
| 2–4 | 13 (9.6%) |
| Total lymphocyte (×106/L) | 1295.2 (973.1–1728.4) |
| B cell (×106/L) | 94.7 (57.1–175.6) |
| T cell (×106/L) | 916.6 (639.4–1221.1) |
| NK cell (×106/L) | 258 (164.4–360.1) |
| CD4+ T (×106/L) | 475.9 (302.4 - 668) |
| CD8+ T (×106/L) | 340.1 (237.5 - 493.3) |
| CD4+CD45RA− T (×106/L) | 348.3 (218.3 - 510.1) |
| CD4+CD45RA+ T (×106/L) | 109.1 (49.4 - 189.1) |
| CD4+CD28+ T (×106/L) | 413.1 (257.7 - 613.7) |
| CD8+CD28+ T (×106/L) | 152.2 (94.9 - 219.7) |
| CD8+DR+ T (×106/L) | 176.3 (112.3 - 264.2) |
| CD8+CD38+ T (×106/L) | 151.7 (91.3 - 208.9) |
| CD4+ T/lymphocyte (%) | 36.1 (29.1 - 45.4) |
| CD8+ T/lymphocyte (%) | 26.9 (21.7 - 35.4) |